These innovative compounds represent a significant progression in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose https://deweylbrx564972.liberty-blog.com/39366336/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide